The reviewed clinical evidence does not establish fat loss from taking MOTS-c. Its mouse findings, endogenous human measurements and a recruiting treatment protocol answer different questions. The FDA status page separates research from routine commercial supply.
In mice, MOTS-c curbed weight gain on a high-fat diet
The fat-loss reputation rests on two sets of mouse studies. In the 2015 study that named the peptide, mice on a high-fat diet given MOTS-c for 8 weeks weighed about 20% less than untreated mice on the same diet [2]. FDA's summary adds that the treated mice burned more energy, stored less fat in the liver and did not develop the high insulin levels the diet caused [1].
A 2019 study in mice whose ovaries had been removed, a model of menopause-related weight gain, found that 12 weeks of MOTS-c meant less weight gain, less fat build-up and more brown-fat activity [3]. As FDA summarizes them, both measured weight gain that was prevented, not weight lost by mice that were already heavy.
| Study | Subjects | Design | Result on weight or fat |
|---|---|---|---|
| Lee 2015 | Mice on a high-fat diet | 8 weeks of treatment vs untreated | About 20% lower weight; less liver fat |
| Lu 2019 | Mice after ovary removal | 12 weeks of treatment vs saline | Less weight gain; less fat build-up |
| Ozkaya 2025 | 85 adults, 48 with obesity | Cross-sectional blood levels, no treatment | No difference in levels by obesity (p = 0.395) |
| NCT07505745 | 120 adults with prediabetes (planned) | Randomized, placebo-controlled | No results; narrative mentions weight/waist, structured outcomes omit them |
Sources: FDA briefing on MOTS-c, July 2026; PubMed; ClinicalTrials.gov.
How long these effects took in mice is laid out in how long MOTS-c takes to work.
The proposed mechanism is AMPK in muscle, so far shown in mice
MOTS-c is thought to act on skeletal muscle through AMPK, the cell's energy sensor that exercise also switches on. In the 2015 mouse work, the metabolic effects disappeared when AMPK signaling was blocked, which FDA reads as the effect being mediated "at least in part" by AMPK [1].
That is also why it is banned in sport. WADA's Prohibited List names MOTS-c under S4.4.1, activators of AMP-activated protein kinase [7]. How long it stays detectable is covered in how long MOTS-c stays in your system.
Endogenous human measurements do not establish treatment benefit
The reviewed published sources do not establish an administered-MOTS-c treatment outcome, so human data describe the body's own MOTS-c, not treatment. A 2025 study of 85 adults found serum levels of 14.33 pg/mL in people with obesity and 13.67 pg/mL in people at a normal weight, a difference that was not significant (p = 0.395) [4].
Levels rose with insulin resistance and fell with age. That runs against the simple story that people with obesity are short of MOTS-c. The study measured levels at one point in time, so it can't show cause in either direction.
Even the measurements are uncertain. An anti-doping lab found that natural MOTS-c levels read by a commercial antibody kit in 20 healthy people could not be confirmed by mass spectrometry [5]. Exercise does raise the body's own MOTS-c, in muscle and blood, according to a 2021 study; those people were sampled, not treated [6].
"Boosts metabolism" claims run ahead of the data
The reviewed sources do not establish a clinical metabolic benefit from administered MOTS-c. FDA identified no human pharmacokinetic study in its assessment; Knoop’s laboratory experiment examined breakdown in human blood outside the body [1] [5]. That experiment does not establish active exposure, clearance or clinical benefit after injection in a person.
Mouse doses also don't translate to people, and these mouse studies injected MOTS-c into the abdominal cavity [1]. Safety in people is unknown; see is MOTS-c safe.
The ongoing trial has no results
The current NCT07505745 record lists 120 estimated participants, recruiting at a site in China, with no posted results. Structured primary outcomes are insulin sensitivity at 12 weeks and adverse events through 16 weeks. Its detailed narrative also names body weight and waist circumference, although those are absent from the structured outcome list. That reporting difference prevents a categorical claim that weight will not be measured [8].
If weight loss is the goal, approved options exist
FDA's own review of MOTS-c makes the point: "There are FDA-approved drug products for weight reduction in patients with obesity" [1]. Those drugs have trial data in people, labels and known side-effect rates. MOTS-c has none of those.
A prescriber can tell you whether an approved option fits you. Some people ask about combining MOTS-c with newer weight drugs; that question is covered in MOTS-c and retatrutide together. How this site reads FDA's documents is set out in how we check.